P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials

Authors

Devika Aggarwal
Kirtipal Bhatia, Beaumont Health Resident
Zainali S Chunawala
Remo H M Furtado
Debabrata Mukherjee
Simon R. Dixon, Beaumont Health
Vardhmaan Jain
Sameer Arora
Thomas A Zelniker
Eliano P Navarese

Document Type

Article

Publication Date

3-21-2022

Publication Title

European heart journal open

Abstract

AIM: To compare the efficacy and safety of P2Y

METHODS AND RESULTS: Medline, Embase, and Cochrane Central databases were searched to identify randomized trials comparing monotherapy with a P2Y

CONCLUSION: P2Y

Volume

2

Issue

2

First Page

oeac019

Recommended Citation

Aggarwal D, Bhatia K, Chunawala ZS, Furtado RHM, Mukherjee D, Dixon SR, et al P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. Eur Heart J Open. 2022 Mar 21;2(2):oeac019. doi: 10.1093/ehjopen/oeac019. PMID: 35919116.

DOI

10.1093/ehjopen/oeac019

ISSN

2752-4191

PubMed ID

35919116